Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALLO
ALLO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALLO News
Allogene Therapeutics to Participate in Investor Conferences
Feb 05 2026
Newsfilter
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
Jan 21 2026
Yahoo Finance
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Dec 16 2025
Benzinga
Allogene Secures Global Control of Cema-Cel, Interim Analysis Set for 1H 2026
Dec 15 2025
Globenewswire
Allogene Secures Full Global Control of Cema-Cel Following Arbitration Ruling
Dec 15 2025
Newsfilter
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
Oct 10 2025
NASDAQ.COM
Keysight Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Oct 10 2025
Benzinga
JP Morgan Lowers Allogene Therapeutics Rating to Underweight
Oct 10 2025
Benzinga
Krystal Biotech Shares Rise Following FDA Approval for Vyjuvek Label Revision
Sep 16 2025
NASDAQ.COM
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Aug 14 2025
Yahoo Finance
Allogene Q2 Cash Tops $300 Million
Aug 13 2025
NASDAQ.COM
JMP Securities Reiterates Market Perform on Allogene Therapeuticsto Market Perform
Aug 04 2025
Benzinga
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Aug 04 2025
Benzinga
JP Morgan Downgrades Allogene Therapeutics to Neutral
Aug 04 2025
Benzinga
Show More News
